Pfizer promotes 'underappreciated' R&D pipeline
This article was originally published in Scrip
Executive Summary
The new in-house buzzword for Pfizer's research and development pipeline isn't catchy, but it seems to accurately describes investor attitudes toward the pharmaceutical giant's R&D programs: underappreciated.